You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 11,026,939

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,026,939 protect, and when does it expire?

Patent 11,026,939 protects INGREZZA and INGREZZA SPRINKLE and is included in two NDAs.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 11,026,939

Scope and claims summary:

Title:	High dosage valbenazine formulation and compositions, methods, and kits related thereto
Abstract:	Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
Inventor(s):	Moore, Jr.; Richard Alexander (San Diego, CA), McClelland; Gregory A. (San Diego, CA), O{grave over ( )}Brien; Christopher F. (Vashon, WA)
Assignee:	Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:	17/074,278
Patent Claim Types: see list of patent claims	Use; Compound; Dosage form;

Drugs Protected by US Patent 11,026,939

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			A METHOD OF TREATING HUNTINGTON'S CHOREA	⤷ Subscribe
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF TARDIVE DYSKINESIA	⤷ Subscribe
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			A METHOD OF TREATING HUNTINGTON'S CHOREA	⤷ Subscribe
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y			TREATMENT OF TARDIVE DYSKINESIA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,026,939

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	112819	⤷ Subscribe
Australia	2018335259	⤷ Subscribe
Brazil	112020005373	⤷ Subscribe
Canada	3076000	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.